A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Na�ve Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Read time: 1 mins
Last updated:23rd Oct 2009
To evaluate progression-free survival time of subjects treated with EMD 1201081 + cetuximab compared to cetuximab alone in cetuximab-na�ve subjects with recurrent and/or metastatic SCCHN who have progressed on a cytotoxic therapy.
|Study start date||2009-10-23|